Cargando…
Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study
PURPOSE: To report the incidence, clinical features, potential risk factors, and outcomes of intraocular inflammation (IOI) following brolucizumab in Indian eyes. METHODS: All consecutive patients diagnosed with brolucizumab-induced IOI from 10 centers in eastern India between October 2020 and April...
Autores principales: | Chakraborty, Debdulal, Mondal, Soumen, Sengupta, Sabyasachi, Abbas, Zahir, Chandra, Khushboo, Boral, Subhendu, Maiti, Aniruddha, Roy, Sangeeta, Mukherjee, Angshuman, Das, Arnab, Chakraborty, Somnath, Nag, Pinaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391460/ https://www.ncbi.nlm.nih.gov/pubmed/37203069 http://dx.doi.org/10.4103/IJO.IJO_2688_22 |
Ejemplares similares
-
Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes – A multicenter retrospective study
por: Chakraborty, Debdulal, et al.
Publicado: (2022) -
Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty, Debdulal, et al.
Publicado: (2021) -
Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series
por: Chakraborty, Debdulal, et al.
Publicado: (2022) -
Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study – Fifty-Two-Week Outcomes
por: Chakraborty, Debdulal, et al.
Publicado: (2022) -
Role of intravitreal brolucizumab with intravitreal rtPA and pneumatic displacement for submacular hemorrhage: A case series
por: Chakraborty, Debdulal, et al.
Publicado: (2022)